Baseline Values of Circulating IL-6 and TGF-ß Might Identify Patients with HNSCC Who Do Not Benefit from Nivolumab Treatment.

Merlano, Marco Carlo; Paccagnella, Matteo; Denaro, Nerina; Abbona, Andrea; Galizia, Danilo; Sangiolo, Dario; Gammaitoni, Loretta; Fiorino, Erika; Minei, Silvia; Bossi, Paolo; Licitra, Lisa; Garrone, Ornella.

Afiliação

Merlano MC; Candiolo Cancer Institute, FPO-IRCCS Candiolo, 10060 Torino, Italy.
Paccagnella M; Translational Oncology ARCO Foundation, 12100 Cuneo, Italy.
Denaro N; Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milano, Italy.
Abbona A; Translational Oncology ARCO Foundation, 12100 Cuneo, Italy.
Galizia D; Candiolo Cancer Institute, FPO-IRCCS Candiolo, 10060 Torino, Italy.
Sangiolo D; Department of Oncology, University of Turin, 10060 Torino, Italy.
Gammaitoni L; Candiolo Cancer Institute, FPO-IRCCS Candiolo, 10060 Torino, Italy.
Fiorino E; Department of Oncology, University of Turin, 10060 Torino, Italy.
Minei S; Post-Graduate School of Specialization Medical Oncology, University of Bari "A. Moro", 70120 Bari, Italy.
Bossi P; Medical Oncology, A.U.O. Consorziale Policlinico di Bari, 70120 Bari, Italy.
Licitra L; Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, Public Health, University of Brescia, 25123 Brescia, Italy.
Garrone O; Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, 20133 Milan, Italy.